{"id":"effervescent-and-buffered-alendronate","safety":{"commonSideEffects":[{"rate":"5-20","effect":"Gastrointestinal upset (nausea, dyspepsia, abdominal pain)"},{"rate":"0.1-1","effect":"Esophageal irritation or ulceration"},{"rate":"1-10","effect":"Musculoskeletal pain"},{"rate":"1-5","effect":"Headache"},{"rate":"<1","effect":"Atypical femoral fractures (rare, long-term use)"},{"rate":"<1","effect":"Osteonecrosis of the jaw (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bisphosphonates like alendronate are taken up by osteoclasts during bone resorption and inhibit the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway essential for osteoclast function and survival. This leads to decreased bone turnover and increased bone mineral density. The effervescent and buffered formulation enhances gastrointestinal absorption and tolerability compared to standard alendronate.","oneSentence":"Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:10.971Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women"},{"name":"Osteoporosis in men"},{"name":"Glucocorticoid-induced osteoporosis"},{"name":"Paget's disease of bone"}]},"trialDetails":[{"nctId":"NCT05325515","phase":"PHASE4","title":"The Effect of Effervescent Alendronate on Bone Turnover","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2021-10-01","conditions":"Osteopenia or Osteoporosis","enrollment":64},{"nctId":"NCT03435094","phase":"","title":"Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes","status":"UNKNOWN","sponsor":"Labatec Pharma SA","startDate":"2018-02-25","conditions":"Osteoporosis, Postmenopausal","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Effervescent and buffered alendronate","genericName":"Effervescent and buffered alendronate","companyName":"Aarhus University Hospital","companyId":"aarhus-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alendronate is a bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and blocking farnesyl pyrophosphate synthase in the mevalonate pathway. Used for Osteoporosis in postmenopausal women, Osteoporosis in men, Glucocorticoid-induced osteoporosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}